Biologics and Viral Analytics and Characterization

Pharmaron’s Gene Therapy CDMO, located in Liverpool, UK, provides analytical capabilities for analysis of biologics and viral vectors from early phase to market authorization. Our analytical toolkit supports biological, physiochemical and biophysical characterization of all biologics product modalities and addresses the unique challenges presented by advanced therapies. Our team utilizes state-of-the-art analytical automation to increase sample throughput for process development and characterization studies.

View as PDF: Biologics and Viral Analytics and Characterization


  • Method development with focus on using ultra-sensitive methodologies
  • Development of platform and bespoke analytics including bioassays for release, stability and in-process analysis
  • Analytical release testing using our validation ready AAV and recombinant protein platform analytical release kit
  • Phase-appropriate method validation and method transfer
  • Process characterization expedited with use of high-throughput techniques
  • Stability study design, execution and shelf-life assessment
  • Specialist knowledge in low endotoxin recovery studies
  • Advanced analytical toolkit for product characterization, comparability and forced degradation studies
  • Identification and evaluation of critical quality attributes
  • Design and justification of phase appropriate product release specifications
  • Critical starting materials stability and release testing
  • Authoring CMC sections for regulatory submission


  • Intact mass analysis
  • Peptide mapping
  • CE-SDS
  • AUC
  • Cryo-EM
  • Mini-TEM
  • ddPCR
  • Capsid ELISA
  • Mini-TEM
  • AUC
  • SEC
  • DLS
  • DSC
  • Infectivity
  • Transgene quantity (CBPA, ddPCR)
  • Functionality (flow cytometry, microscopy)


More Information

Biologics & CGT Home

Learn About Our Services